Who Owns Aligos Therapeutics Stock?
NASDAQ: ALGSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 1:06 PM ET
Ownership breakdown
- Held by institutions
- 42.16%
- Held by insiders
- 10.64%
- Institutional holders
- 38
- Institutions 42.2%
- Insiders 10.6%
- Public and other 47.2%
Who owns Aligos Therapeutics stock?
Institutional investors own about 42.2% of Aligos Therapeutics's shares, spread across 38 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 10.64% of ALGS.
The largest institutional holders are Deep Track Capital, Lp (7.11%), Alyeska Investment Group, L.p. (6.60%) and Sio Capital Management, LLC (5.24%). Together, the top 10 institutions control 33.1% of shares outstanding. In their latest filings, 2 of the top 10 institutions increased their ALGS positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ALGS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Deep Track Capital, Lp | 444.11K | 7.11% | 0.0% |
| Alyeska Investment Group, L.p. | 412.00K | 6.60% | 0.0% |
| Sio Capital Management, LLC | 327.24K | 5.24% | 0.0% |
| Marshall Wace LLP | 246.58K | 3.95% | -7.7% |
| Woodline Partners LP | 177.36K | 2.84% | 0.0% |
| Vanguard Capital Management LLC | 175.54K | 2.81% | -1.5% |
| Baker Bros. Advisors, LP | 83.06K | 1.33% | 0.0% |
| HHLR Advisors, LTD | 76.25K | 1.22% | 0.0% |
| Shaw D.E. & Co., Inc. | 66.46K | 1.06% | +505.4% |
| UBS Group AG | 59.99K | 0.96% | +61.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ALGS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 128.77K | 2.06% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 46.77K | 0.75% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 22.12K | 0.35% |
| iShares Trust-iShares Micro-Cap ETF | 16.32K | 0.26% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Micro Cap Portfolio | 8.33K | 0.13% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 7.55K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 6.14K | 0.10% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Portfolio | 3.57K | 0.06% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 3.18K | 0.05% |
| Dimensional ETF Trust-Dimensional U.S. Small Cap ETF | 2.81K | 0.04% |
Frequently asked questions
Who is the largest shareholder of Aligos Therapeutics?
Deep Track Capital, Lp is the largest institutional shareholder of ALGS, owning 7.11% of shares outstanding (444.11K shares) as of its latest 13F filing.
What percentage of Aligos Therapeutics is owned by institutions?
Institutions own about 42.2% of ALGS shares and 47.2% of the public float.
How much of Aligos Therapeutics do insiders own?
Insiders, such as officers and directors, own about 10.64% of ALGS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.